Prostatype Genomics AB announced that interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the Company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US study with Prostatype® and data from other conducted studies, will be included in the Company's upcoming Medicare application in the United States with the aim to get Prostatype® approved for reimbursement in fourth quarter 2024.

Complete interim data from the Uppsala study will be presented at the annual American Urological Association (AUA) conference in the United States in May 2024, one of the leading scientific conferences in the field of urology on a global level. The company's Medicare application to get Prostatype® approved for reimbursement in the United States, with expected submission in Q2-Q3 2024 and expected approval in fourth quarter 2024, will include data from the ongoing US study, as well as data from other studies including the Uppsala study. The United States is the world's largest market for gene testing of patients with established prostate cancer, with current annual sales of approx.

SEK 2 billion (USD 200 million), and the Company estimates the total market potential in the United States to be approx. SEK 6 billion (USD 600 million) per year. The genetic test Prostatype® is used as a supplementary guidance for urologists when selecting treatment type for patients diagnosed with prostate cancer.

Prostate cancer affects around one in eight men, of which approx. 50-90% undergo radical treatment. According to the Company's assessment, about a third of these radical treatments could be avoided or postponed if the patients were correctly risk-classified, and there is thus a great need for improved guidance when deciding on treatment type.